Apoptotic Effect of Co-Treatment with a Natural Product, Chios Gum Mastic, and a Synthetic Chenodeoxycholic Acid Derivative, HS-1200, on Human Osteosarcoma Cells.
10.11637/kjpa.2008.21.2.167
- Author:
Ji Hak MIN
1
;
Min Jeong KIM
;
In Ryoung KIM
;
Seung Eun LEE
;
Hyun Ho KWAK
;
Gyoo Cheon KIM
;
Hae Ryoun PARK
;
Sang Hun SHIN
;
Chul Hoon KIM
;
Na Young JEONG
;
Hongsuk SUH
;
Bong Soo PARK
Author Information
1. Department of Oral Anatomy, School of Dentistry, Pusan National University, Korea. parkbs@pusan.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Chios Gum Mastic;
Synthetic Chenodeoxycholic Acid (CDCA) Derivatives;
HS-1200;
Apoptosis;
Human Osteosarcoma cells
- MeSH:
Apoptosis;
Chenodeoxycholic Acid;
DNA;
Electrophoresis;
Exudates and Transudates;
Gingiva;
Humans;
Membrane Potential, Mitochondrial;
Osteosarcoma;
Pistacia;
Proteasome Endopeptidase Complex;
Proteins;
Resins, Plant;
Trees
- From:Korean Journal of Physical Anthropology
2008;21(2):167-180
- CountryRepublic of Korea
- Language:English
-
Abstract:
Chios gum mastic (CGM) is a resinous exudate obtained from the stem and the main leaves of Pistacia lenticulus tree native to Mediterranean areas. Recently it reported that CGM induced apoptosis in a few cancer cells in vitro. It has been reported that the synthetic chenodeoxycholic acid (CDCA) derivatives showed apoptosis-inducing activity on various cancer cells in vitro. This study was undertaken to investigate the synergistic apoptotic effect of co-treatment with a natural product, CGM and a CDCA derivative, HS-1200 on human osteosarcoma (HOS) cells. To investigate whether the co-treatment of CGM and HS-1200 compared with each single treatment efficiently reduced the viability of HOS cells, MTT assay was conducted. Induction and augmentation of apoptosis were confirmed by DNA electrophoresis, Hoechst staining and DNA hypoploidy, Westen blot analysis and immunofluorescent staining were performed to study the alterations of the expression level and translocation of apoptosis-related proteins in co-treatment. Furthermore, proteasome activity and mitochondrial membrane potential (MMP) change were also assayed. In this study, HOS cells co-treated with CGM and HS-1200 showed several lines of apoptotic manifestation whereas each single treated HOS cells did not. Although the single treatment of 40 microgram/mL CGM or 25 micrometer HS-1200 for 24 h did not induce apoptosis, the cotreatment of them induced prominently apoptosis. Therefore our data provide the possibility that combination therapy of CGM and HS-1200 could be considered as a novel therapeutic strategy for human osteosarcoma.
